External ValidationExternal presentations at the Society for the Immunotherapy of Cancer meeting were considered positive for Turnstone's approach.
Financial StabilityThe company holds $28.9 M in cash, equivalents, and short-term investments, expected to fund operations through mid-2026.
Scientific AdvancementsThe evidence that selecting a specific 12-genome signature meaningfully increases TIL yield and potency is encouraging for Turnstone Biologics.